BMEA Stock Analysis: Buy, Sell, or Hold?
BMEA - Biomea Fusion, Inc. Common Stock
$1.73
0.14 (8.81%)
▲
5d:
+28.15%
30d:
+37.3%
90d:
+22.7%
WAIT
LOW Confidence
Analysis Updated: Aug 25, 2026 12:00 AM ET
Earnings: Aug 04, 2026
0d
Get Alerted When BMEA Hits Your Target Price
Join 10,000+ traders who never miss a move
You're in! Check your email to confirm and set your target price.
100% Free
No spam, ever
Unsubscribe anytime
Interactive Price Chart (1 Month)
Loading chart...
Loading historical data...
Bottom Line:
⏸️ WAIT FOR BETTER ENTRY: BMEA is 21.8% above its trading range ($1.42). While momentum could continue, risk/reward favors waiting for a pullback.
⏸️ WAIT FOR BETTER ENTRY: BMEA is 21.8% above its trading range ($1.42). While momentum could continue, risk/reward favors waiting for a pullback.
In-depth Analysis How we analyze
Valuation Analysis: BMEA is currently trading at $1.73, which is considered extended relative to its 30-day fair value range of $1.20 to $1.42.
Technical Outlook: Technically, BMEA is in a downtrend. Immediate support is located at $1.26, while resistance sits at $1.81. The stock is showing strong short-term momentum, up 8.8% recently.
Market Sentiment: BMEA scores 15/100 on our bottoming-setup gauge. Note this measures entry quality, not trend direction — a low score can mean the chart is extended after a strong run (don't chase) or still falling without stabilization; better entries typically come after a pullback toward the 20-day average. Wall Street analysts see significant upside, with an average price target of $6.50 (+275.7%). Current signals suggest waiting for a better entry point before initiating new positions.
Technical Outlook: Technically, BMEA is in a downtrend. Immediate support is located at $1.26, while resistance sits at $1.81. The stock is showing strong short-term momentum, up 8.8% recently.
Market Sentiment: BMEA scores 15/100 on our bottoming-setup gauge. Note this measures entry quality, not trend direction — a low score can mean the chart is extended after a strong run (don't chase) or still falling without stabilization; better entries typically come after a pullback toward the 20-day average. Wall Street analysts see significant upside, with an average price target of $6.50 (+275.7%). Current signals suggest waiting for a better entry point before initiating new positions.
Quick Decision Summary
Current Position
EXTENDED
Historical Trading Range
$1.20 -
$1.42
Company Quality Score
40/100
(SELL)
Volume Confirmation
HIGH
Confidence Score
21.1%
All Signals
- BEARISH: Price significantly overextended (+21.8% above its trading range)
- BEARISH: Weak technical setup (15/100)
- BULLISH: High volume confirmation
- BULLISH: Strong upward momentum (+8.8%)
- BULLISH: Trading 275.7% below Wall St target ($6.50)
- WARNING: Composite score 40/100 in the bottom quintile — this cohort historically lags the market
Trading Range Analysis
30-Day Trading Range
$1.20 -
$1.42
Current vs Trading Range
EXTENDED
Support & Resistance Levels
Support Level
$1.26
Resistance Level
$1.81
Current Trend
Downtrend
Technical data as of
Aug 25, 2026
Fundamental Context
Forward P/E (Next Year Est.)
-1.84
Wall Street Target
$6.50
(+275.7%)
Share & Embed Analysis
Last updated: August 25, 2026 8:25 PM ET
Data refreshes hourly during market hours. Next update: 9:25 PM
Data refreshes hourly during market hours. Next update: 9:25 PM
🔥 Top Stocks Breaking Out Now
| Ticker | Score | Recommendation | Change % |
|---|
Technical Signals Check
Is BMEA showing a specific setup today?
Insider Activity (6 Months)
0
Buys
0
Sells
0
Net
NEUTRAL
Top Rated Biotechnology Stocks
Top-rated stocks in Biotechnology by analyst ratings.
| Stock | Analyst Consensus | Analyst Target | Tradestie Score |
|---|---|---|---|
|
NTLA
Intellia Therapeutics Inc |
STRONG BUY
29 analysts |
$24 | 38 SELL |
|
REGN
Regeneron Pharmaceutical… |
STRONG BUY
25 analysts |
$840 | 41 HOLD |
|
MLTX
MoonLake Immunotherapeut… |
STRONG BUY
16 analysts |
$29 | 60 BUY |
|
JAZZ
Jazz Pharmaceuticals PLC |
STRONG BUY
18 analysts |
$281 | 48 HOLD |
|
KYMR
Kymera Therapeutics Inc |
STRONG BUY
20 analysts |
$131 | 39 SELL |
